Cargando…
GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors ha...
Autores principales: | Jiang, Kaili, Tang, Xia, Guo, Jing, He, Rui, Chan, Shingpan, Song, Xiaojuan, Tu, Zhengchao, Wang, Yuting, Ren, Xiaomei, Ding, Ke, Zhang, Zhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290231/ https://www.ncbi.nlm.nih.gov/pubmed/34114373 http://dx.doi.org/10.1002/cam4.4041 |
Ejemplares similares
-
GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
por: Wang, Yuting, et al.
Publicado: (2020) -
YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018) -
Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance
por: Lu, Xiaoyun, et al.
Publicado: (2017) -
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways
por: Ye, Wei, et al.
Publicado: (2016) -
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo
por: Wang, Jie, et al.
Publicado: (2022)